L.M. Kohn & Company Boosts Holdings in Pfizer Inc. (NYSE:PFE)

L.M. Kohn & Company lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 14.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,314 shares of the biopharmaceutical company’s stock after purchasing an additional 4,574 shares during the period. L.M. Kohn & Company’s holdings in Pfizer were worth $1,051,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of PFE. Fred Alger Management LLC increased its stake in Pfizer by 7.4% during the 3rd quarter. Fred Alger Management LLC now owns 102,668 shares of the biopharmaceutical company’s stock worth $2,971,000 after buying an additional 7,076 shares in the last quarter. Rockefeller Capital Management L.P. increased its position in shares of Pfizer by 2.0% during the third quarter. Rockefeller Capital Management L.P. now owns 1,630,089 shares of the biopharmaceutical company’s stock worth $47,169,000 after purchasing an additional 32,524 shares in the last quarter. Northwest & Ethical Investments L.P. raised its stake in Pfizer by 3.0% in the 3rd quarter. Northwest & Ethical Investments L.P. now owns 263,531 shares of the biopharmaceutical company’s stock valued at $7,627,000 after purchasing an additional 7,799 shares during the last quarter. Teachers Insurance & Annuity Association of America purchased a new position in Pfizer in the 3rd quarter valued at $35,000. Finally, Vinva Investment Management Ltd boosted its stake in Pfizer by 312.5% during the 3rd quarter. Vinva Investment Management Ltd now owns 193,465 shares of the biopharmaceutical company’s stock worth $5,628,000 after purchasing an additional 146,564 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $26.21 on Friday. The stock has a market cap of $148.53 billion, a PE ratio of 35.42, a P/E/G ratio of 0.70 and a beta of 0.67. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a fifty day simple moving average of $27.83 and a 200-day simple moving average of $28.49. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the business earned ($0.17) earnings per share. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.41%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Analyst Ratings Changes

A number of brokerages have recently commented on PFE. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Sanford C. Bernstein started coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $32.92.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.